Korea’s Dong-A Wins WHO Prequalification For TB Generic Of Lilly’s Seromycin As Firm Moves Up Value Chain
This article was originally published in PharmAsia News
Executive Summary
WHO prequalification clears path for Korea’s Dong-A to move from an API supplier of cycloserine to an exporter of finished products.
You may also be interested in...
Korea's Yuhan Signs Deal To Sell Gilead's Viread In Korea
SEOUL - South Korea's Yuhan Corp. said it signed an agreement March 30 with Gilead Sciences Inc. to sell the latter's hepatitis B drug Viread (tenofovir) in Korea, beginning in the second half of this year after winning approval from Korea FDA
EstechPharma In Talks With German Company For MRI Contrast Medium Agents; Korean API Makers Struggle For Global Foothold
SEOUL - South Korea's active pharmaceutical ingredient company EstechPharma is currently in talks with a German-based multinational company, likely Bayer Schering Pharma, to sell its two generic MRI contrast medium products
Early-Stage Idiopathic Pulmonary Fibrosis (IPF) Candidates Race to Phase III
Multiple IPF drugs are being rushed into Phase III based on early-stage signals of efficacy and safety presented at the ATS meeting. Scrip spoke with the University of Pittsburgh's Kevin Gibson about the candidates, trial design, combination therapy and limitations of current therapy.